The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - MSD
Consulting or Advisory Role - Kyowa Hakko Kirin; Novartis; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst)
Chronomodulated (CRM) Bimonthly 48 Hour (Hr) 5-Fluorouracil (FU), Folinic Acid (FA), Oxaliplatin (OXA) 'FOLFOX CRM' in FU-Refractory (FUR) Advanced Colorectal Cancer (ACRC) Patients (Pts): Phase II Study.
 
Akihito Kawazoe
No Relationships to Disclose
 
Yasutoshi Kuboki
Honoraria - Bayer; Taiho Pharmaceutical
 
Tomohiro Nishina
Research Funding - Dainippon Sumitomo Pharma; MSD
 
Eiji Shinozaki
Honoraria - Bayer; Chugai Pharma; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Satoshi Yuki
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Ono Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Hideaki Bando
Research Funding - AstraZeneca; Sysmex
 
Koji Takahashi
No Relationships to Disclose
 
Yuichi Mikamoto
No Relationships to Disclose
 
Hiromi Hasegawa
No Relationships to Disclose
 
Nami Hirano
No Relationships to Disclose
 
Shogo Nomura
No Relationships to Disclose
 
Yosuke Togashi
No Relationships to Disclose
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo; Kyowa Hakko Kirin; Merck Serono; Ono Pharmaceutical (Inst); Taiho Pharmaceutical; Zenyaku Kogyo
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Bayer; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical